Study on preparation of Fe₃O₄@lapatinib nanoparticles for application as a targeted drug delivery system in the treatment of breast cancer
Main Article Content
Abstract
Systems for targeted drug delivery in the treatment of cancer using nanoparticles are currently of interest to many domestic and foreign scientists. In this work, for application as a target drug delivery system in the treatment of breast cancer Fe3O4@lapatinib nanoparticles were prepared by coprecipitation of solutions of Fe2+ and Fe3+ salts in alkaline, followed by purification in a magnetic separation system. Physicochemical properties of nanoparticles were studied and determined by XRD, TEM, DLS, HPLC, VSM, AAS and zeta potential methods. The results showed that the size of Fe3O4@lapatinib nanoparticles is in the range of 10 to 40 nm, hydrodynamic diameter is 27.4 ± 0.6 nm, saturation magnetization is 39.1 ± 3.1 emu/g, Fe content is 16.35 ± 0.97 mg/ml, lapatinib content is 8.08 ± 0.06 mg/ml, and the zeta potential is -16.2 ± 1.3 mV. Thus, the obtained Fe3O4@lapatinib nanoparticles are fully suitable for targeted drug delivery in the breast cance treatment
Article Details
Keywords
Fe₃O₄@lapatinib nanoparticles, co-precipitation, breast cancer, targeted drug delivery
References
[2]. Ministry of Health, List of 9498 techniques in medical test and treatment performed at Bach Mai Hospital, (2014).
[3]. Beverly Moy, et al., "Lapatinib", Nature reviews drug discovery, 6, pp (2007), 10.1038/nrd2332.
[4]. Nguyen Thi Kim Thanh, "Clinical Applications of Magnetic Nanoparticles", CRC Press, pp <4-54>, 2018, https://doi.org/10.1201/9781315168258
[5]. Domenico Bilancia, et al., "Lapatinib in breast cancer", Annals of Oncology, 18 Suppl 6, pp
[6]. Rüdiger Lawaczeck, Michael Menzel, Pietsch, Hubertus, "Superparamagnetic iron oxide particles: contrast media for magnetic resonance imaging", Applied Organometallic Chemistry, 18, pp <506-513>, (2004), https://doi.org/10.1002/aoc.753.
[7]. Qiyi Feng, et al., "Uptake, distribution, clearance, and toxicity of iron oxide nanoparticles with different sizes and coatings", Scientific Reports, 8, pp <2082>, (2018), 10.1038/s41598-018-19628-z.
[8]. Luong Huynh Vu Thanh, et al., "Synthesis of surface functionalized Fe3O4@SiO2 nanomaterials with chitosan", Can Tho University Science Magazine, 57, pp <10-20>, (2021), 10.22144 /ctu.jvn.2021.032.
[9]. Dhrisya Chenthamara, et al., "Therapeutic efficacy of nanoparticles and routes of administration", Biomaterials Research, 23, pp <20>, (2019), 10.1186/s40824-019-0166-x.
[10]. Li Tang, et al., "Investigating the optimal size of anticancer nanomedicine", Proc Natl Acad Sci U S A, 111, pp <15344-9>, (2014), 10.1073/pnas.1411499111.
[11]. Nazanin Hoshyar, et al., "The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction", Nanomedicine (Lond), 11, pp <673-92>, (2016), 10.2217/nnm.16.5.
[12].Yudelson, Joseph S., "Preparation and magnetic properties of very small magnetite-dextran particles", United States Patent, (1994).
[13]. Dhirender Singh, et al., "Formulation design facilitates magnetic nanoparticle delivery to diseased cells and tissues", Nanomedicine (Lond), 9, pp <469-85>, (2014), 10.2217/nnm.14.4.
[14]. Patricia A Hudgins, et al., "Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study", American Journal of Neuroradiology, 23, pp <649-56>, (2002).
[15].McHenry, M.E., "Magnetic Steels",
Encyclopedia of Materials: Science and Technology, pp.< 4961-4964>, (2001).
[16]. Jeffrey D Clogston, Patri, Anil K, "Zeta potential measurement", Methods Mol Biol, 697, pp <63-70>, (2011), 10.1007/978-1-60327-198-1_6.
[17]. Magdalena Kędzierska, et al., "The Synthesis Methodology of PEGylated Fe(3)O(4)@Ag Nanoparticles Supported by Their Physicochemical Evaluation", Molecules, 26, pp <1-17>, (2021), 10.3390/molecules26061744